What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.”In the company’s words, NCT05405595 on ClinicalTrials.gov
- Tested for
- Advanced/Metastatic Solid Tumors
- Main trialPhase 1/2
- “This is a Phase 1b/2, open-label, dose escalation, dose expansion and dose optimization study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors. The study drug ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).”In the company’s words, NCT05405595 on ClinicalTrials.gov
Other drugs for Advanced/Metastatic Solid Tumors
- PembrolizumabMerck & Co. · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Intismeran autogeneMerck & Co. · Moderna · Phase 3
- LenvatinibMerck & Co. · Eisai Inc. · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- CalderasibMerck & Co. · Phase 3
Coming up1
- 30 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Jun 2027 | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | |
| Phase 1/2Completed | 29 Jan 2024 | ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026